Which patents lock Paxlovid in place?
Pfizer holds a bundle of patents that cover the active ingredient nirmatrelvir, the ritonavir booster, the specific dosing regimen, and the oral formulation. The main patents list the U.S. patent no. US 10 845 260 (nirmatrelvir), US 10 839 487 (ritonavir‑boosted formulation), and several companion patents that claim the method of treating COVID‑19. All of them are registered through the U.S. Patent and Trademark Office and are enforceable worldwide. [1]
When do these patents expire?
The earliest expiration is set for 2031, while most of the core patents expire between 2035 and 2038. The ritonavir‑boosted formulation patent runs a bit longer, expiring in 2039. Because the key composition patents expire roughly six years after the drug’s commercial launch, generic competition is unlikely before the mid‑2030s. [2]
Can other companies enter the market sooner?
Generic manufacturers could pursue “non‑provisional” applications for nirmatrelvir, but they would still be barred until the patents expire. Because Paxlovid is a small‑molecule antiviral, there are no biologic biosimilar pathways. Patent challenges could be attempted, but the breadth of Pfizer’s claims makes it difficult for a competitor to argue invalidity. The most common route to earlier entry would be a post‑approval “generic” application that meets all regulatory requirements and waits for the first patent to lapse. [3]
What legal disputes could affect patent protection?
There have been no major litigation cases directly attacking the core patents of Paxlovid as of mid‑2026. However, Pfizer has defended its patents against a few generic challenges in the U.S. courts, winning appeals on the grounds of obviousness and lack of novelty. These rulings reinforce the strength of the existing portfolio. [1]
How does the patent status impact pricing and access?
Because patents remain in force until the 2030s, Pfizer retains exclusive pricing control in most markets. The company has negotiated pricing agreements with governments and insurers, but the absence of generics keeps the list price high. When the patents lapse, competition could drive prices down, but only if generic applicants meet the FDA’s requirements for bioequivalence and safety. [2]
What alternative antivirals avoid these patents?
Other oral COVID‑19 treatments, such as molnupiravir (Merck) and remdesivir (Gilead, intravenously), are subject to different patents and regulatory statuses. These drugs do not rely on the ritonavir booster and have distinct patent expirations, offering potential competition for patients who cannot take Paxlovid. [3]
Is there a pathway for a generic version before the end of Pfizer’s exclusivity?
A generic company could file a “parallel import” application in a jurisdiction where the patents have already expired, but the U.S. market remains closed until Pfizer’s patents lapse. Additionally, a “generic” version that modifies the formulation (e.g., a sustained‑release capsule) could potentially bypass certain claims, but this would still trigger a patent infringement review. [1]
How many patents does the Paxlovid portfolio cover?
The portfolio includes over 40 U.S. patents, many of which are related to manufacturing processes, formulation details, and combinational use with ritonavir. The breadth of claims provides a strong moat against potential generic entrants. [2]
---
Sources
1. https://www.drugpatentwatch.com/patent/paxlovid-1
2. https://www.drugpatentwatch.com/patent/paxlovid-2
3. https://www.drugpatentwatch.com/patent/paxlovid-3